In This Section

Program: Tuesday, February 25

Sunday, Feb. 23 Monday, Feb. 24 Wednesday, Feb. 26

tuesday, february 25

*-Short talk from proffered abstract

Tuesday, February 25

CONTINENTAL BREAKFAST

7-8 a.m.

Major Symposia 4-5 

8-9:30 a.m.

Major Symposium 4: Neoadjuvant Immunotherapy 

Session Chair: Christian Blank, Netherlands Cancer Institute, Amsterdam, Netherlands

  • 8:05 a.m. | Neoadjuvant immunotherapy in lung cancer: preclinical models, clinical trials and reverse translation
    Tina Cascone, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 8:25 a.m. | Neoadjuvant immunotherapy: What can we learn from melanoma to optimize patient outcomes
    Georgina V. Long, University of Sydney, Sydney, NSW, Australia
  • 8:45 a.m. | Full personalization of neoadjuvant therapy: The next steps
    Christian Blank
  • 9:05 a.m. | Discussion / Q&A

Major Symposium 5: Myeloid Cell Checkpoints 

Session Chair: Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York

  • 8:05 a.m. | Leveraging single technologies to engineer the immune system
    Ido Amit, Weizmann Institute of Science, Rehovot, Israel
  • 8:25 a.m. | Spatio-temporal regulation of tumor associated macrophages
    Florent Ginhoux, Gustave Roussy, Villejuif, France
  • 8:45 a.m.
    Miriam Merad
  • 9:05 a.m. | Discussion / Q&A

BREAK

9:30-9:50 a.m.

Major SymposiA 6-7 

10-11:30 a.m.

Major Symposium 6: engineered T Cells for Solid Tumors 

Session Chair: Philip D. Greenberg, Fred Hutchinson Cancer Center, Seattle, Washington

  • 10:05 a.m.
    Kole Roybal, University of California, San Francisco, California
  • 10:25 a.m.
    Christine E. Brown, City of Hope National Medical Center, Duarte, California
  • 10:45 a.m.
    Philip D. Greenberg
  • 11:05 a.m. | Discussion / Q&A

Major Symposium 7: Inflammation and Cancer 

Session Chair: Robert Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania

  • 10:05 a.m.
    Michael Karin, University of California, San Diego, California
  • 10:25 a.m. | KRAS inhibitors and modulation of inflammation and immunity
    Robert H. Vonderheide
  • 10:45 a.m. | Theraparticles for inside-out neutrophil control in acute inflammation
    Lola Eniola Adefeso, University of Illinois Chicago, Chicago, Illinois
  • 11:05 a.m. | Discussion / Q&A

BREAK

11:30 a.m.-12 p.m.

keynote session 3

12-1 p.m.

Session Chair: Philip D. Greenberg, Fred Hutchinson Cancer Center, Seattle, Washington

  • 12:05 p.m.
    Crystal L. Mackall, Stanford University School of Medicine, Stanford, California
  • 12:35 p.m.
    Carl H. June, University of Pennsylvania, Philadelphia, Pennsylvania

Spotlight on Proffered Papers Session 2

1-1:45 p.m.

  • 1:04 p.m. | CD4+ T cell rest and activation is enabled by centralized control of state specific regulatory genes*
    Maya Arce, University of California, San Francisco, California
  • 1:11 p.m. | Generation of T cell responses against broad KRAS hotspot neoantigens using a single large-scale process as the basis for an adoptive cell therapy or for TCR discovery*
    Vikram Juneja, BioNTech US, Inc., Cambridge, Massachusetts
  • 1:18 p.m. | Genome-wide CRISPR screens in CD8+ T cells identify cullin-RING E3 ubiquitin ligase complex as a negative regulator of long-term effector function*
    Justin R. Saco, UCLA David Geffen School of Medicine, Los Angeles, California
  • 1:25 p.m. | Immunogenic landscape and therapeutic targeting of mutant NRAS ”public” neoantigens*
    Inaki Etxeberria, Memorial Sloan Kettering Cancer Center, New York, New York
  • 1:32 p.m. | The RAS(ON) G12D-selective inhibitor RMC-9805 synergizes with anti- PD-1 to extend durability of antitumor activity in KRAS G12D-driven preclinical cancer models*
    Marie J.C. Menard, Revolution Medicines, Redwood City, California
  • 1:39 p.m.
    Speaker to be announced

Poster Session B / Exhibit Show / Lunch

1:45-4:45 p.m.

spotlight SESSIONS 3 AND 4

5-6:20 p.m.

Spotlight Session 3: Tertiary Lymphoid Structures in Cancer

Session Chair: Daniela Thommen, Netherlands Cancer Institute, Amsterdam, Netherlands

  • 5:05 p.m. | Cell interactions that modulate PD-1+ CD8 T cell responses
    Alice O. Kamphorst, Icahn School of Medicine at Mount Sinai, New York, New York
  • 5:25 p.m. | Impact of tertiary lymphoid structures on the tumor-specific T cell landscape
    Daniela Thommen
  • 5:45 p.m. | Antibody responses in intra-tumoral Tertiary Lymphoid Structures antagonize the progression of human cancer
    Jose R. Conejo-Garcia, Duke Cancer Institute, Durham, North Carolina
  • 6:05 p.m. | Discussion / Q&A

Spotlight Session 4: CAR-T in vivo Delivery 

Session Chair: Michael Birnbaum, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

  • 5:05 p.m. | Antigen-specific viral targeting of T cells
    Michael Birnbaum
  • 5:25 p.m. | Direct in vivo transduction of T and NK cells to treat B cell malignancies
    Saar Gill, University of Pennsylvania, Philadelphia, Pennsylvania
  • 5:45 p.m.
    Jennifer Hamilton, Azalea Therapeutics, Berkeley, California
  • 6:05 p.m. | Discussion / Q&A

evening off

6:20 p.m.